AstraZeneca PLC (NASDAQ:AZN) Shares Bought by West Oak Capital LLC

West Oak Capital LLC raised its position in AstraZeneca PLC (NASDAQ:AZN) by 1,318.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,483 shares of the company’s stock after purchasing an additional 2,308 shares during the period. West Oak Capital LLC’s holdings in AstraZeneca were worth $163,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. A. D. Beadell Investment Counsel Inc. purchased a new position in shares of AstraZeneca during the fourth quarter valued at approximately $876,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of AstraZeneca by 0.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 192,348 shares of the company’s stock valued at $12,603,000 after purchasing an additional 607 shares in the last quarter. Baker Tilly Wealth Management LLC grew its stake in AstraZeneca by 14.0% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 9,465 shares of the company’s stock worth $620,000 after buying an additional 1,165 shares during the period. First Hawaiian Bank raised its position in AstraZeneca by 60.7% in the fourth quarter. First Hawaiian Bank now owns 22,529 shares of the company’s stock valued at $1,476,000 after purchasing an additional 8,514 shares during the period. Finally, Fulton Bank N.A. lifted its position in AstraZeneca by 49.4% during the 4th quarter. Fulton Bank N.A. now owns 13,937 shares of the company’s stock worth $913,000 after acquiring an additional 4,608 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ AZN traded up $0.43 during mid-day trading on Friday, reaching $67.01. 5,671,171 shares of the company traded hands, compared to its average volume of 4,304,024. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm has a market cap of $207.77 billion, a PE ratio of 32.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The stock has a fifty day simple moving average of $66.20 and a 200-day simple moving average of $75.01. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS. Equities research analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.